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A B S T R A C T
Previous studies have shown that people with schizophrenia have high rates of Obstructive Sleep Apnoea (OSA). Despite this, intervention studies to treat OSA in this
population have not been undertaken. The ASSET (Assessing Sleep in Schizophrenia and Evaluating Treatment) pilot study investigated Continuous Positive Airway
Pressure (CPAP) treatment of severe OSA in participants recruited from a clozapine clinic in Adelaide. Participants with severe untreated OSA (Apnoea-Hypopnoea
Index (AHI) > 30), were provided with CPAP treatment, and assessed at baseline and six months across the following domains: physical health, quality of sleep,
sleepiness, cognition, psychiatric symptoms and CPAP adherence. Six of the eight ASSET participants with severe OSA accepted CPAP. At baseline, half of the cohort
had hypertension, all were obese with a mean BMI of 45, and they scored on average 1.47 standard deviations below the normal population in cognitive testing. The
mean AHI was 76.8 and sleep architecture was markedly impaired with mean rapid eye movement (REM) sleep 4.1% and mean slow wave sleep (SWS) 4.8%. After
six months of treatment there were improvements in cognition (BACS Z score improved by an average of 0.59) and weight loss (mean weight loss 7.3 ± 9 kg). Half of
the participants no longer had hypertension and sleep architecture improved with mean REM sleep 31.4% of the night and mean SWS 24% of the night. Our data
suggests CPAP may offer novel benefits to address cognitive impairment and sleep disturbance in people with schizophrenia.
1. Introduction
Obstructive sleep apnoea (OSA) is a nocturnal breathing disorder
caused by repeated collapse of the upper airway during sleep, resulting
in repetitive arousal. OSA is associated with poor cardiovascular health
due to physiological changes related to intermittent hypoxia, and re-
duced quality of life due to sleep disturbance (Al Lawati et al., 2009).
Continuous positive airway pressure (CPAP) reverses these pathophy-
siological changes and improves quality of life. (Jing et al., 2008). OSA
is prevalent in people with schizophrenia due to high rates of obesity
(Galletly et al., 2012) and men with schizophrenia are 2.9 times more
likely to have OSA than age matched general population controls
(Myles et al., 2018). A recent systematic review estimated that 19–57%
of people with schizophrenia suffer comorbid OSA (Myles et al., 2016);
these rates are much higher than that seen in the general population
(Heinzer et al., 2015). Despite this, there is minimal literature reporting
outcomes following treatment of OSA in this population.
The standard treatment for OSA is nocturnal CPAP which involves
wearing a face or nasal mask that applies a continuous pressure to splint
the upper airway during sleep. Effective CPAP treatment prevents ob-
structive events that cause repetitive hypoxia and arousals; and restores
normal sleep architecture. In general population studies, not all people
with OSA can tolerate CPAP, and the duration of CPAP use per night
impacts on the clinical efficacy (Weaver et al., 2007). Mean CPAP ad-
herence of four hours per night is considered the minimum required for
efficacy. Treatment outcomes and adherence rates for CPAP in people
with schizophrenia have not been reported previously and would be
valuable in determining whether treatment of OSA in this population is
efficacious.
In the general population CPAP reverses morbidity associated with
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OSA including impaired cognition and vigilance, insulin resistance, and
hypertension (Al Lawati et al., 2009; Jing et al., 2008; Patel et al.,
2003). Ratings of quality of life, daytime sleepiness, depression and
anxiety also improve with CPAP. Thus, treatment of OSA in people with
schizophrenia could potentially improve not only cardiometabolic risk
factors, but also neurocognitive and functional outcomes. OSA and
schizophrenia (Afonso et al., 2011) are associated with disruptions to
sleep architecture, as such it is also important to determine whether
sleep architecture is normalized to the same extent in people with
schizophrenia compared to the general population.
This pilot study examined subjects diagnosed with schizophrenia
and comorbid OSA. Subjects undertook psychiatric, cardiometabolic,
cognitive and quality of life assessments prior to undergoing treatment
with CPAP. The participants were then followed longitudinally during
6 months of CPAP treatment to determine adherence, efficacy and ac-
ceptability of treatment, and changes in baseline measures. To our
knowledge this is the first prospective assessment of CPAP usage in
people with schizophrenia and comorbid OSA.
Specifically, we aimed to determine:
1. The efficacy of and adherence to CPAP treatment in people with
schizophrenia and comorbid OSA.
2. Changes in anthropometric measurements before and following six
months of CPAP treatment
3. Changes in psychiatric symptoms, quality of life measures, sleep
quality measures and cognitive measures before and during CPAP
treatment.
2. Materials and methods
2.1. Population
Subjects were recruited from a psychiatric outpatient clinic in
Adelaide, South Australia. Inclusion criteria included males and females
aged 18–64 years, a current clinical diagnosis of schizophrenia or
schizoaffective disorder, currently prescribed clozapine and a diagnosis
of severe OSA made during assessment in the ASSET study. Exclusion
criteria included inability to provide informed consent and a diagnosis
of sleep disordered breathing made prior to enrolment in the ASSET
study. Subjects were recruited between January 2015 and March 2016.
Ethics approval was provided by The Queen Elizabeth Hospital Ethics
Committee. All participants gave written informed consent.
2.2. Measures
A trained research nurse collected data on each participant at
baseline at the Lyell McEwin Hospital Research Department, South
Australia. Demographic and anthropometric data was recorded on the
day prior to or the day following at-home diagnostic polysomnography
(PSG) and included age, sex, medical history, prescribed medications,
height, weight, waist and neck circumference, body mass index (BMI)
and blood pressure. Waist circumference was measured to the nearest
0.5 cm at the level of the iliac crest following two normal breaths.
Abdominal obesity was defined as a waist circumference ≥ 94 cm for
men and ≥80 cm for women. Hypertension was diagnosed if the person
had a systolic blood pressure ≥ 130 mm Hg and/or a diastolic
pressure ≥ 85 mm Hg. Psychopathological measures included the
Positive And Negative Symptoms Scale (PANSS) (Kay et al., 1987),
Montgomery Asperger's Depression Rating Scale (MADRS) (Williams
and Kobak, 2008) and Personal and Social Performance Scale (PSP)
(Morosini et al., 2000). Cognition was assessed using the Brief Assess-
ment of Cognition for Schizophrenia (BACS) (Keefe et al., 2008). The
results of the BACS were recorded as Z scores across individual domains
and as a total score for Verbal Memory (VM), Digit Sequencing (DIGI),
Token Motor Task (TMT), Verbal Fluency (Fluency), Symbol Coding
(SC), the Tower of London (TL) and Total z score (Total). A score of zero
indicates that the participant is on par with the general population
mean. Scores in the negative range indicate cognitive decrements and
are presented as standard deviations below the normal population
means. Validation studies in people with schizophrenia score 1.5
standard deviations below the normal population mean. Subjective
sleep quality was assessed with the Pittsburg Sleep Quality Inventory
(PSQI) (Buysse et al., 1989), severity of insomnia with Insomnia Se-
verity Index (ISI) (Morin et al., 2011), Restless Legs Scale (RLS) (Group,
2003), and sleep related quality of life with Functional Outcomes of
Sleep Questionnaire (FOSQ) (Weaver et al., 1997).
Following recruitment and baseline measures subjects underwent
at-home eight channel PSG performed using an Embletta ×100 (Natus
Medical Inc., USA) or Somte (Compumedics, Australia) portable sleep
recorder administered in the participants home by a trained psychiatric
registrar. PSG data were manually staged by a BRPT registered Sleep
Technician supervised by a board registered sleep physician at the
Adelaide Institute for Sleep Health (ASIH) using the 2007 AASM al-
ternate criteria to obtain an Apnoea-Hypopnoea Index (AHI) (Iber et al.,
2007).
Eight subjects had an AHI > 30 events/h and were considered to
have severe OSA, all were offered and accepted CPAP titration. We
targeted an AHI > 30 events/h because this severity of OSA has been
associated with a higher risk of cardiovascular events. Five of the
participants then underwent laboratory-based CPAP titration overnight
with additional PSG recording and one underwent at-home APAP ti-
tration using a Respironics REMstar Auto System (Philips, Netherlands).
One subject underwent at-home APAP titration at their request. One
subject failed CPAP titration due to discomfort in the laboratory setting
and one developed nausea when using the mask. Both of these subjects
declined at-home titration. The remaining six formed the cohort re-
ported in this paper. These six subjects were provided with CPAP ma-
chines from the Adelaide Institute for Sleep Health and received routine
clinical care from this service consisting of an initial physician review
and a one-hour education session with a trained CPAP nurse. Ongoing
care included physician follow up with an associated nurse review
every three months and phone contact from the nurse between reviews.
The PSG data provided a range of sleep measures including AHI, mean
apnoea/hypopnea duration, longest apnoea duration, number of desa-
turations < 90%, total sleep duration, sleep latency, duration of each
stage of sleep, duration of slow wave sleep (SWS), total sleep time, dura-
tion of non-rapid eye movement (non-REM) and rapid eye movement
(REM) sleep, sleep efficiency, number of arousals and REM latency.
Participants were followed up after six months of CPAP use using
the same anthropometric, psychopathological, cognitive and sleep
quality measures as at baseline.
CPAP usage was determined by analyzing subject specific CPAP
telemetry recorded using Encore Anywhere (Philips, Netherlands)
software. Recorded CPAP adherence data included mean daily CPAP
usage, percentage usage of > 4 h, mean hourly usage on days used,
average usage across all days, percentage of night with large leaks,
average AHI and average snoring index.
2.3. Outcomes
The primary outcome was efficacy of CPAP treatment determined
by changes in sleep architecture and AHI, and adherence to CPAP.
Secondary outcomes were changes in anthropometric measures, psy-
chopathological measures, sleep quality measures and cognition at six-
month follow-up.
2.4. Statistical methods
Statistical analyses were performed using SPSS 24 (IBM, New York).
We present descriptive statistics including frequencies, means and
standard deviations. No inferential statistics were performed due to the
small sample size.
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3. Results
104 subjects were approached for at-home PSG screening as part of
the ASSET pilot study. 30 subjects were recruited and underwent
baseline study measures of whom 8 were diagnosed with severe OSA.
Reasons for declining participation in at-home PSG screening were not
collected in these non-consenting patients. Eight subjects from the
ASSET study with severe OSA (AHI > 30 events/h) were offered CPAP,
six (5 male, 1 female) of whom successfully underwent CPAP titration
and completed six months of treatment (see Fig. 1).
The sample was young and had high rates of obesity and hy-
pertension. Mean age of the sample was 37.4 years (SD 12.3 years),
mean BMI was 45 (SD 9.6 range: 36.4–62.1), mean waist circumference
was 137.4 cm (SD 9.8 cm range: 126 cm–154 cm), mean neck cir-
cumference was 47.7 cm (SD 4.5 cm, range: 44 cm–53 cm), and mean
AHI was 76.8 (SD 45, range: 40.2–134.5).
3.1. CPAP acceptability and sleep architecture pre and post-CPAP
introduction
Five CPAP titrations occurred in the laboratory setting, allowing
PSG to be recorded throughout CPAP initiation. PSG measures of sleep
architecture at baseline and after CPAP of the five subjects are pre-
sented in Table 1. At baseline the sample had extremely severe OSA
Approached for 
assessment of eligibility 
(n = 104)
Declined assessment (n = 
74)
Not meeting inclusion 
criteria   (n = 0)
Recruited to ASSET 






















All 6 initiated on CPAP 
completed 6 month 
follow up.  (N = 6)
Participants with AHI<30 
were provided with no 
further follow up (N=22).
Two participants failed 
CPAP titration. (N=2)
Fig. 1. Consort diagram.
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with AHIs that ranged from 37.6–134.5 (mean 83.3), and associated
disruption of normal sleep architecture. The proportion of restorative
SWS and REM sleep were reduced across the sample with mean time in
SWS at baseline of 4.8% and mean time in REM of 4.1%. There was
consistent improvement across these sleep domains with treatment,
with REM sleep rebounding to 31.4% of the night and SWS 24% of the
night.
3.2. CPAP adherence
CPAP usage was assessed using Philips Encore Anywhere software.
This allowed determination of residual AHI with treatment, mask
leakage, snoring, and percentage of the night CPAP was being used.
Usage data for the first month is presented in Table 2, and usage data
for the first six months of treatment is presented in Table 3. CPAP use
of > 4 h per night is considered adequate adherence and is sufficient to
substantially reverse levels of sleepiness (Weaver et al., 2007). In the six
months of treatment the mean proportion of nights when CPAP was
used for ≥4 h was 60%, and mean usage was 7.6 h/night, indicating
adequate adherence. Mask leak and residual AHI are indicators of the
effectiveness and proficiency with using CPAP. The average residual
AHI across the first six months of treatment was 3.6 events/h and
percentage of the night in large leak 9.7%, indicating adequate treat-
ment effect.
3.3. Physical health
Height, weight, body mass index (BMI), waist circumference (WC),
and neck circumference (NC) before and during treatment are pre-
sented in Table 4, blood pressure and heart rate before and during
treatment are presented in Table 5. The participants had high rates of
obesity and hypertension (100%) for such a young sample after six
months of CPAP treatment, with no other interventions, five partici-
pants lost weight and three no longer had hypertension.
3.4. Psychiatric symptom scales
Psychiatric symptom measures were recorded at baseline and after
six months of CPAP therapy and are presented in Table 6. Higher scores
on the PANSS indicates more severe psychosis, higher scores on the
MADRS indicates more severe depression and higher scores on the PSP
indicate better overall functioning. There were no observable changes
in psychopathology scales in these participants. The baseline scores
were below diagnostic and clinically significant ranges.
3.5. Sleep quality scales
Sleep quality measures were recorded at baseline and after six months
of CPAP therapy and are presented in Table 7. Higher scores on the PSQI,
FOSQ, ESS, ISI and RLS indicate worse sleep quality in those domains.
Sleep quality and functional consequences of poor sleep did not con-
sistently change with CPAP. Insomnia severity reduced consistently, but
the threshold for clinical insomnia is a score of 15, and as such the baseline
results were not within the diagnostic range for most participants.
3.6. Cognition
Cognition was recorded at baseline and after six months of CPAP
therapy using the BACS, the results are presented in Table 8. At baseline
the mean BACS total Z score was −1.47 and Verbal memory (short term
memory) −1.89. CPAP demonstrated improvements across several
domains including Verbal memory 0.55 and the overall change was
0.59 (SD 0.25).
4. Discussion
This pilot study demonstrates CPAP treatment is effective at nor-
malizing sleep architecture disturbances in subjects with schizophrenia
and comorbid severe OSA. Average measures of CPAP use were ade-
quate at one month and were sustained over a six-month follow-up
period. Average daily usage stabilized between 5 and 6 h on average
whilst percentage of days with usage > 4 h a night was maintained at or
above 60% for the duration of follow-up. This latter criterion is the
threshold for adequate CPAP adherence for clinical efficacy. CPAP ad-
herence has not been investigated previously in schizophrenia, and our
results indicate that this treatment is acceptable, and usage is sustained
in the long term. After six months treatment, the AHI remained sup-
pressed, indicating effective reversal of obstructive apnoea, and there
was a reduction in time spent with mask leakage, indicating that sub-
jects became more proficient at fitting their masks correctly.
Table 1
Sleep architecture at baseline and immediately after CPAP initiation.
ID AHI % non-REM (stage 1&2 plus SWS) % slow wave sleep (SWS) % REM sleep
Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP
1 73.4 1.1 97.6 84.6 4 20.4 2.4 15.4
2 130.7 7.9 98.8 66.5 0.2 21.6 1.2 33.5
3 134.5 3.7 98.9 54.7 7.9 32.8 1.1 45.3
4 37.6 4.4 84.4 76.6 12.1 17.5 15.6 23.4
5 40.2 10.7 100 60.7 0 28.1 0 39.3
Mean (SD) 83.3 (47.2) 5.5 (3.7) 95.94 (6.5) 68.62 (12) 4.8 (5.2) 24 (6.2) 4.1 (6.5) 31.4 (12)
Table 2
CPAP usage during the first month of treatment.
Days used Percentage of days ≥4 h Average usage in hours on days
used
Average usage in hours on all
days
Average % of the night in large
leak
Average AHI
1 24 61.3 6.1 4.7 0.3 2.2
2 19 35.5 4.4 2.8 1.4 8.5
3 30 96.8 9.2 8.9 4.4 4.8
4 29 84.4 7.75 7 21.7 1.7
5 14 37.5 9.5 4 6.7 4.4
6 29 80.6 8.75 8.15 35.2 7.3
Mean (SD) 24 days (6.5 days) 66% (25%) 7.6 h (2 h) 5.9 h (2.4 h) 11.6% (14%) 4.8 (2.7)
Abbreviations: Apnoea-Hypopnoea Index (AHI).
H. Myles et al. Schizophrenia Research: Cognition 15 (2019) 14–20
17
Downloaded for Anonymous User (n/a) at The University of Adelaide from ClinicalKey.com.au by Elsevier on October 15, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
Treatment with CPAP normalized sleep architecture with a rebound in
REM sleep from an average of 4.1% to 31.4%, and a tripling of slow wave
sleep. This may be important clinically as slow wave sleep is associated
with rejuvenation and neuroendocrine homeostasis. Interestingly at
follow-up after CPAP and in spite of substantial improvement in sleep
architecture, there was little change in patient reported subjective sleep
quality scales. There was a slight improvement in ISI scores, no change in
FOSQ scores and a trend towards worsening of PSQI scores. A disconnect
between objective functional outcomes and subjective impairment in-
dicators have been previously noted in people with schizophrenia
(Strassnig et al., 2018), our data similarly suggests subjective self-ratings
are not an accurate reflection of objective sleep quality in people with
schizophrenia.
Participants treated with CPAP had an average 7.3 kg weight loss at
6 months with an average 2.5 point reduction in BMI and an average
4.5 cm reduction in waist circumference. This is a novel finding that
warrants further evaluation. Obesity is highly prevalent in people with
schizophrenia and weight loss is difficult to achieve and maintain. All of
our participants were taking clozapine, the most obesogenic anti-
psychotic drug. In the general population, treatment with CPAP is not
associated with weight loss (Redenius et al., 2008). The loss of weight
in our subjects may reflect improved vitality and an increase in physical
activity; future studies should include objective measures of activity
such as actigraphy to explore this possibility. In addition, restoration of
normal oxygenation during sleep may be associated with a normal-
ization of insulin resistance, which might advantageously influence
macronutrient metabolism.
Hypertension also improved, with a mean reduction of 12.1 mm Hg
in systolic blood pressure and 4.8 mm Hg in diastolic blood pressure. All
six participants met criteria for hypertension at baseline, but only three
met these criteria at six months. These changes are consistent with
general population studies of CPAP treatment in OSA (Martínez-García
et al., 2013). At baseline all of our participants met criteria for obesity,
all had at-risk waist circumference and all had hypertension. People
with schizophrenia have much higher rates of metabolic syndrome than
the general population (Galletly et al., 2012), and our findings indicate
improvement in some of the components of metabolic syndrome.
Our subjects were relatively young (mean age 37.4 years, range 26
to 57). The early onset of obesity and metabolic disturbances in people
with schizophrenia has been documented previously (Foley et al., 2013;
Galletly et al., 2012). Our findings emphasize that OSA, like obesity and
metabolic syndrome, can occur early in this population. Young people
with the risk factors for OSA (obesity, elevated waist and neck cir-
cumference, smoking, alcohol abuse, sedating medications) should be
screened using an objective measure such as home PSG, as they may
well have undiagnosed OSA.
OSA is associated with cognitive deficits, particularly: attention,
vigilance, short term/working memory, executive functioning and
motor functioning. People with normal or low baseline cognitive
function are more vulnerable to the cognitive deficits of OSA, and these
deficits have been found to normalize with CPAP treatment (Barnes
et al., 2004; Matthews and Aloia, 2011; Pan et al., 2015). The me-
chanisms underlying the cognitive deficits caused by OSA are poorly
understood but may be explained to some degree by sleep fragmenta-
tion, sleep deprivation, hypoxia, chronic inflammation and cerebellar
vascular damage. CPAP treatment improves performance across mul-
tiple cognitive domains (Pan et al., 2015) resulting in improved func-
tional and occupational outcomes in the general population (Tregear
et al., 2010). Translation of this benefit to people with schizophrenia
and comorbid OSA would be an innovative means of modifying cog-
nitive symptoms and real-world functional outcomes: currently an area
of unmet clinical need. Our pilot results indicate that treatment of se-
vere OSA with CPAP improves cognition in people with schizophrenia.
Cognitive function improved with an average overall Z score im-
provement on the BACS of 0.59. Cognitive impairment is a major de-
terminant of functional outcome in Schizophrenia (Green et al., 2000)
and has been identified as a crucial target for treatment (MATRICS)
(Green et al., 2004) but, as with obesity, achieving meaningful change
has been difficult.
This study provides proof of concept that treatment of OSA with
CPAP is feasible in people with schizophrenia and offers insight into the
novel benefits treatment may have on sleep quality, cardiometabolic
Table 3
CPAP usage during the first six months of treatment.
Days used Percentage of days ≥4 h Average usage in hours on days
used
Average usage in hours on all
days
Average % of the night in large
leak
Average AHI
1 148 67 6.85 5.5 1.7 1.6
2 115 39.6 5.2 3.3 3.9 6.8
3 177 89 8.7 8.5 6.8 1.9
4 109 53.5 7.5 4.5 11.8 1.5
5 72 34.6 8.8 3.5 8.4 2.7
6 158 78.3 8.75 7.5 26 7.3
Mean 130 days (38 days) 60.3% (21.5%) 7.6 h (1.4 h) 5.4 h (2.1 h) 9.7% (8.7%) 3.6 (2.7)
Abbreviations: Apnoea-Hypopnoea Index (AHI).
Table 4
Weight, BMI, WC and NC changes after 6 months treatment with CPAP.
ID Age Height Weight BMI WC NC
Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP
1 26 176 192.5 183.3 62.14 59.79 154 151 53 Missing
2 40 170 136 125.3 47 43.01 135 133 53 46
3 30 175 142.4 121.3 46.5 39.61 139.5 134 43 Missing
4 45 181 133.2 126 40.69 38 140 124 45 43
5 26 186 125.8 131 36.4 37.86 130 134 44 44
6 57 158 92.6 92 36.86 36 126 120 48 46
Mean (SD) 137.1(32.3) 129.8 (29.7) 44.9 (9.5) 42.4 (8.9) 137.4 (9.7) 137.2 (10.7) 47.5 (4) 44.6 (1.5)




Abbreviations: continuous positive airway pressure (CPAP), body mass index (BMI), waist circumference (WC), neck circumference (NC).
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outcomes and cognition in this population. The diagnostic measures
and treatment interventions undertaken in this study are standard
practice, not investigational and importantly are broadly available and
easily accessible in most public health services. We have demonstrated
that the investigation and treatment of OSA is well tolerated and ac-
ceptable in a population of subjects with serious mental illness, thus
indicating that stable schizophrenia itself is neither a barrier to effective
treatment nor an excuse for clinical apathy when a sleep disorder is
suspected. Further more highly powered randomized trials should be
performed in the future to determine whether CPAP treatment of OSA
comorbid with schizophrenia has a clinically relevant effect on cogni-
tive and psychopathological symptoms.
4.1. Limitations
Whilst our results are important and encouraging, several limitations to
our study should be acknowledged. Firstly, the small numbers and ob-
servational nature of the study do not allow causal inferences to be made
from the follow-up data presented and are hypothesis generating only.
Similarly, the absence of a control group makes it difficult to determine
whether changes in cognition are independently associated with CPAP
treatment, further controlled studies are required to validate our results.
Measures of fasting blood sugar, cholesterol and triglycerides, and insulin
resistance were not recorded and should be included in future studies of
CPAP treatment of OSA in schizophrenia. Secondly, whilst our data does
support the acceptability of PSG and CPAP these results may not be
broadly generalisable to typical populations of people with psychotic ill-
ness. Whilst consecutive recruitment was undertaken, subjects refusing to
participate in screening for OSA may have introduced selection bias where
those less likely to adhere to CPAP were self-excluded from screening.
Recruitment was also from a clozapine clinic, potentially representing a
population where psychotic symptoms may be better controlled thus ad-
herence to treatment more likely. Similarly, universal clozapine exposure
may have biased results in our cohort as the effect of clozapine on sleep
architecture is poorly understood. Clozapine is highly sedating and may
confound interpretation of objective daytime sleepiness measures that
Table 5
Blood pressure and HR changes after 6 months treatment with CPAP.
ID Systolic BP Diastolic BP Hypertensiona
Y v N
Heart rate
Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP
1 139 145 75 88 Y Y 95 106
2 127 121 88 87 Y Y 88 93
3 134 109 79 74 Y N 102 82
4 153 120 92 84 Y N 90 92
5 133 143 92 80 Y Y 116 102
6 154 129 97 81 Y N 112 90
Mean (SD) 140 (11.1) 127.8 (14.1) 87.2 (8.5) 82.3 (5.2) 50% reduction in hypertension 100.5 (11.6) 94.2 (8.6)
Mean change (SD) −12.1 (18) −4.8 (10.2) −6.3 (14)
a Hypertension was diagnosed if the person had a systolic blood pressure ≥ 130 mm Hg and/or a diastolic pressure ≥ 85 mm Hg.
Table 6
Psychiatric symptom scales before and after 6 months treatment with CPAP.
ID PANSS MADRS PSP
Baseline CPAP Baseline CPAP Baseline CPAP
1 73 62 4 Missing 49 60
2 42 54 2 2 72 60
3 86 92 12 4 33 37
4 43 57 0 3 60 61
5 63 67 6 10 60 60
6 54 52 4 0 60 50
Mean 60.2 (17.4) 64 (14.8) 4.8 (4.6) 3.8 (3.8) 55.6 (13.3) 54.7 (9.6)
Mean change (SD) 3.8 (9.3) −1.0 (5.0) −1.0 (8.7)
Abbreviations: Positive and Negative Symptom Scale (PANSS), Montgomery Aspergers Depression Rating Scale (MADRS), Personal and Social Performance Scale
(PSP), continuous positive airway pressure (CPAP).
Table 7
Sleep quality measures before and after six months of CPAP.
ID PSQI FOSQ ISI RLS ESS
Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP
1 7 11 30 35 11 6 7 0 4 4
2 7 8 39 31 7 1 0 0 9 10
3 4 4 19 27 16 7 11 14 11 3
4 5 4 36 39 5 1 8 5 2 5
5 8 6 31 32 12 8 0 12 3 5
6 3 2 35 31 7 1 0 0 – –
Mean 5.7 5.8 31.7 32.5 9.7 4 4.3 5.2 5.8 (4) 5.4 (2.7)
Mean change (SD) 0.16 (2.1) 0.83 (5.91) −5.6 (1.86) 0.83 (6.43) −0.4 (3.5)
Abbreviations: Pittsburgh Sleep Quality Index (PSQI), Functional Outcomes of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI), Restless Leg Scale (RLS),
Epworth Sleepiness Scale (ESS).
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have been validated in general populations. Thirdly, the study interven-
tions and follow-up may have introduced bias in that subjects may have
felt more encouraged to participate and adhere to treatment. We consider
this unlikely however as the majority of the study was undertaken using
pre-existing sleep services and standard follow-up.
5. Conclusion
People with schizophrenia commonly suffer lifetime disability due
to severe, chronic functional impairment. Our pilot data indicates that
effective treatment of OSA with CPAP therapy is achievable and well
tolerated in people with schizophrenia and may improve cognition,
sleep architecture and cardiometabolic measures, including blood
pressure and weight. There is no previous published literature on the
cognitive and physical outcomes before and after CPAP. Further re-
search such as a randomized controlled trial of CPAP in people with
schizophrenia and OSA, to determine whether CPAP leads to cognitive
enhancement, improves functional outcomes and reduces cardiovas-
cular disease (CVD) risk factors would be beneficial.
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VM DIGI TMT Fluency SC TL Total
Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP Baseline CPAP
1 −2.35 −1.63 −0.81 −2.08 −2.24 −0.52 1.05 0.55 0.03 0.34 0.07 0.07 −1.06 −0.81
2 −1.31 −0.38 0.46 1.22 −0.52 −0.38 −0.35 0.22 0.74 0.34 0.35 0.62 −0.16 0.41
3 −3.50 −2.46 −3.59 −2.58 −1.57 −0.38 −2.16 −2.33 −2.52 −2.2 −1.31 −1.03 −3.64 −2.73
4 −0.69 0.66 −0.56 0.71 −1.18 −1.18 −0.19 0.22 −0.45 −0.29 1.17 1.45 −0.47 0.39
5 −2.25 −2.35 −1.57 −0.05 −0.12 −0.38 −1.83 −1.5 −1.33 −0.69 −0.48 −0.75 −1.88 −1.43
6 −1.21 −1.83 −1.82 −0.81 0.01 1.2 −0.52 −0.68 −1.4 −0.85 −1.58 −1.58 −1.62 −1.13
Mean −1.89 −1.33 −1.32 −0.6 −0.93 −0.27 −0.67 −0.59 −0.82 −0.56 −0.3 −0.2 −1.47 −0.88
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Abbreviations: verbal memory (VM), digit sequencing (DIGI), token motor task (TMT), verbal fluency (fluency), symbol coding (SC), Tower of London (TL).
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